- Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
-
Park JG
- KMID: 2351029
- Clin Mol Hepatol.
- 2015 Sep;21(3):287-294.
- doi: 10.3350/cmh.2015.21.3.287
BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Sorafenib in the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Report of Four Cases
-
Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W
- KMID: 2373217
- Korean J Gastroenterol.
- 2015 Apr;65(4):246-251.
- doi: 10.4166/kjg.2015.65.4.246
With an increasing number of patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT), tumor recurrence remains the main limiting factor for long-term survival. Although sorafenib is available for advanced... -
- CITED
-
- Close
- SHARE
-
- Close
- Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib
-
Choi JI, Imagawa DK, Bhosale P, Bhargava P, Tirkes T, Seery TE, Lall C
- KMID: 1788573
- Clin Mol Hepatol.
- 2014 Jun;20(2):218-222.
- doi: 10.3350/cmh.2014.20.2.218
Hepatocellular carcinomas are highly vascular tumors, showing progressive hypervascularity by the process of neoangiogenesis. Tumor angiogenesis is critical for tumor growth as well as metastatic spread therefore, imaging and quantification... -
- CITED
-
- Close
- SHARE
-
- Close
- Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis
-
Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, Park SY, Tak WY, Kweon YO, Kim BS, Lee CH
- KMID: 2363034
- Clin Mol Hepatol.
- 2016 Mar;22(1):160-167.
- doi: 10.3350/cmh.2016.22.1.160
BACKGROUND/AIMS: Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial. We compared the outcomes of hepatic resection (HR), transarterial chemoembolization (TACE), and sorafenib therapy as treatments for... -
- CITED
-
- Close
- SHARE
-
- Close
